ライフサイエンスコーパス: septic shock

1 ion is detrimental to the juvenile host with septic shock.

2 ong children encountering community-acquired septic shock.

3 ovascular and endothelial alterations during septic shock.

4 acterial clearance in the juvenile host with septic shock.

5 e improved hospital survival in distributive septic shock.

6 ing missed 66 patients with severe sepsis or septic shock.

7 3%), patients had more liver dysfunction and septic shock.

8 s better for patients with severe sepsis and septic shock.

9 enues for a potential therapy of early-stage septic shock.

10 nd incidence of thrombocytopenia are high in septic shock.

11 omputing risk of transition from sepsis into septic shock.

12 PS is critical for antibacterial defense and septic shock.

13 y been proposed to confer protection against septic shock.

14 to improve outcomes in cancer patients with septic shock.

15 in development and progression of pediatric septic shock.

16 ine or vasopressin, or to corticosteroids in septic shock.

17 omidine may decrease norepinephrine doses in septic shock.

18 he impending occurrence of severe sepsis and septic shock.

19 a total of 150,845 visits for severe sepsis/septic shock.

20 f O-GlcNAc stimulation at the early phase of septic shock.

21 ity to adverse outcomes including sepsis and septic shock.

22 essin for other patient-centered outcomes in septic shock.

23 w an increased susceptibility to LPS-induced septic shock.

24 em may cause various autoimmune diseases and septic shock.

25 norepinephrine requirements in experimental septic shock.

26 plicit diagnosis codes for severe sepsis and septic shock.

27 as transferred to the intensive care unit in septic shock.

28 se, we believe, represents the true onset of septic shock.

29 hway in host resistance to endotoxin-induced septic shock.

30 surgical ICU patients with severe sepsis and septic shock.

31 h a liberal strategy in cancer patients with septic shock.

32 hemodynamic support of newborn and pediatric septic shock.

33 were largely resistant to endotoxin-induced septic shock.

34 mortality in children with severe sepsis or septic shock.

35 d eighty-four patients (25.0%) progressed to septic shock.

36 athogenic neutrophil subset in patients with septic shock.

37 ysfunction plus infection, severe sepsis, or septic shock.

38 y lethal immune collapse syndrome similar to septic shock.

39 l factors are involved in the development of septic shock.

40 bacteria may not be the only factor inducing septic shock.

41 mortality in patients with severe sepsis and septic shock.

42 ion that causes widespread tissue damage and septic shock.

43 pisodes of suspected infection and suspected septic shock.

44 T lymphocytes facilitate the pathobiology of septic shock.

45 stablished mortality of IL-15 KO mice during septic shock.

46 ate baseline mortality risk in children with septic shock.

47 that was ongoing at the time of death due to septic shock.

48 lt male C57Black 6 mice, adult patients with septic shock.

49 phrine use of at least 60% for patients with septic shock.

50 ical Modification codes for severe sepsis or septic shock.

51 pathogens is probably critical to outcome in septic shock.

52 ECMO) obtained from three large databases of septic shock.

53 s been identified as a potential therapy for septic shock.

54 ent in 28% of children with severe sepsis or septic shock.

55 thiamine vs placebo for adult patients with septic shock.

56 e followed for the development of sepsis and septic shock.

57 antibiotic administration for patients with septic shock.

58 enetic factors and post-traumatic sepsis and septic shock.

59 t least 1 year following hospitalization for septic shock.

60 the development of post-traumatic sepsis and septic shock.

61 f this combination therapy for patients with septic shock.

62 icated course and mortality in children with septic shock.

63 onth 3 follow-up among children encountering septic shock.

64 for children encountering community-acquired septic shock.

65 may be for patients with suspected sepsis or septic shock.

66 ts a potential new data-driven definition of septic shock.

67 life disability among children encountering septic shock.

68 Critical Sepsis, was defined, approximating septic shock.

69 gy Score 2: 54 +/- 20), 53 (54%) experienced septic shock.

70 coverage to any patient suspected of having septic shock.

71 sin vs. Norepinephrine as Initial Therapy in Septic Shock]).

72 cteristics) was 0.96 (95% CI, 0.96-0.96) for septic shock, 0.97 (0.97-0.97) for acute respiratory fai

73 enomedullin and Outcome in Severe Sepsis and Septic Shock-1) enrolled 583 septic patients.

74 le neutropenia (18 patients [7%]), sepsis or septic shock (11 [5%]), QT prolongation (five [2%]), and

75 ty after 14 days decreased among all groups (septic shock: 12.6% to 6.7%; septic shock with acute res

76 Interventional study in a rat model of septic shock (128 adult males) to assess the effects of

77 ol for rapid identification of patients with septic shock, 2) a "resuscitation and stabilization bund

78 socomial origin (32% vs 20%, P = .014), more septic shock (21% vs 11%, P = .007), and higher Risk-E s

79 ortality rates decreased among patients with septic shock (21.2% to 10.8%) and septic shock with acut

80 -day mortality decreased among patients with septic shock (22.1% to 15.5%), septic shock with acute r

81 The Septic Shock 3.0 definition would have decreased sample

82 nical Modification code for severe sepsis or septic shock; 3,021 of these patients (28%) had an immun

83 5% male; mean +/- SD, 60 +/- 14 yr old) with septic shock (30%), hemorrhagic shock (15%), cardiogenic

84 10.3%), severe sepsis (20.3% vs 10.3%), and septic shock (33.5% vs 15.9%) was higher in prolonged ac

85 Three months following septic shock, 346 of 389 subjects (88.9%) were alive and

86 most costly complications were postoperative septic shock (4.0-fold, 95% CI 3.58-4.43) renal insuffic

87 nd chemotherapy (94 patients) were sepsis or septic shock (46 patients [19%] for quizartinib vs 18 [1

88 Septic shock 48-hour, 3-14-day and greater than 14-day m

89 .9% received starch, and among patients with septic shock, 68.3% had lactate measured and 64% receive

90 without the characteristic) are as follows: septic shock, 7.27 (7.19-7.35); metastatic cancer and ac

91 ication codes for severe sepsis (995.92) and septic shock (785.52) identified a smaller, more accurat

92 pticemia (038.x), severe sepsis (995.92), or septic shock (785.52), as well as all subsequent hospita

93 Among patients with septic shock, a resuscitation strategy targeting normali

94 gies, including periodic fever syndromes and septic shock-a plague on modern medicine.

95 measured by the pSOFA score, and sepsis and septic shock according to the Sepsis-3 definitions.

96 ated Protein C and Corticosteroids for Human Septic Shock, adjunctive hydrocortisone therapy showed a

97 id Treatment in Critically Ill Patients with Septic Shock, adjunctive hydrocortisone therapy showed a

98 rting enzyme inhibitors had a higher risk of septic shock (adjusted hazard ratio, 1.45; 95% CI, 1.26-

99 fected patients: 1) patients in the ICU with septic shock and 2) hospitalized patients with Staphyloc

100 hours and first 24 hours after the onset of septic shock and 30-day in-hospital mortality; 2) determ

101 ases, 9th Edition codes for severe sepsis or septic shock and a positive blood culture during their h

102 id Treatment in Critically Ill Patients with Septic Shock and Activated Protein C and Corticosteroids

103 id Treatment in Critically Ill Patients with Septic Shock and Activated Protein C and Corticosteroids

104 characteristic of critical illnesses such as septic shock and acute respiratory distress syndrome.

105 its potential as a driver of inflammation in septic shock and autoimmune diseases, GSDMD represents a

106 rning algorithm to predict severe sepsis and septic shock and evaluate the impact on clinical practic

107 We then analyze plasma from patients with septic shock and find that increasing levels of IL-6 and

108 id Treatment in Critically Ill Patients with Septic Shock and hydrocortisone at a 50 mg IV bolus ever

109 we validated the known genes and pathways in septic shock and identified the unexplored septic shock-

110 o validate this association in children with septic shock and in a juvenile murine model of sepsis.

111 GITB in transplant patients, complicated by septic shock and multiple organ failure, including acute

112 irculating endothelial progenitor cells from septic shock and nonseptic shock patients showed evidenc

113 s in the durvalumab plus tremelimumab group (septic shock and pneumonitis), and one (<1%) patient in

114 ccurred in one patient in the placebo group (septic shock and pulmonary oedema) and one patient in th

115 Patients with septic shock and S. aureus bacteremia admitted directly

116 his study we selected patients admitted with septic shock and treated for more than 4 days from a pro

117 id Treatment in Critically Ill Patients with Septic Shock) and $30,911 (Activated Protein C and Corti

118 complication of atrial fibrillation and one septic shock) and two due to disease progression.

119 eceiving invasive mechanical ventilation and septic shock, and 0.99 (0.99-0.99) for acute respiratory

120 groups have a 76.5% and 10.4% prevalence of septic shock, and 43% and 18% mortality, respectively.

121 severity score 33); 33% developed sepsis, 6% septic shock, and in-hospital mortality was 14%.

122 LPS can cause death as a result of septic shock, and its lipid A core is the target of poly

123 ects mice against lipopolysaccharide-induced septic shock, and knockdown of Usp15 in Hrd1-knockout ma

124 zyme inhibitors had a higher risk of sepsis, septic shock, and mortality than those receiving angiote

125 hemophagocytic lymphohistiocytosis, sepsis, septic shock, and other conditions were distinctly diffe

126 hemophagocytic lymphohistiocytosis, sepsis, septic shock, and other diagnoses.

127 on score, LogEuroSCORE, acute heart failure, septic shock, and paravalvular complications were risk f

128 Incident thrombocytopenia occurs early in septic shock, and platelet recovery lags behind clinical

129 tric haemorrhage, peritonitis, pneumothorax, septic shock, and sudden death (n=1 of each).

130 the trials were performed in the setting of septic shock, and the most frequent comparator was a com

131 ubpopulation of neutrophils in patients with septic shock, and those with a high percentage of olfact

132 onstrates that early prediction of impending septic shock, and thus early intervention, is possible m

133 ient avoided cost was multiplied by expected septic shock annual incidence.

134 sepsis inpatient admission remain high: for septic shock, approximately 60%; for severe sepsis, appr

135 Critically ill patients with sepsis or septic shock are at an increased risk of death.

136 Children with severe sepsis and septic shock are best identified in the Virtual Pediatri

137 Sepsis and septic shock are common and, at times, fatal in pediatri

138 bradycardia (heart rate, < 80 beats/min) in septic shock are unknown.

139 outcomes in patients with severe sepsis and septic shock as a result of the full implementation of t

140 of vasopressin infusion among patients with septic shock as well as vasoplegic shock after cardiotho

141 ng patients with sepsis who will progress to septic shock, as defined by Sepsis- 3 criteria, with the

142 ally ventilated, and 42% in severe sepsis or septic shock at infection onset.

143 nter this state are highly likely to develop septic shock at some future time.

144 ration of HAT therapy among U.S. adults with septic shock before and after study publication and to c

145 All patients treated for septic shock between 2012 and 2017 with an age greater t

146 ented to the emergency department with early septic shock between October 2008 and April 2014, and we

147 tified 53 differentially expressed pediatric septic shock biomarkers using gene expression data sampl

148 equiring intensive care and/or patients with septic shock), blending together mortality estimates fro

149 xpression indicated a nonsurvival outcome in septic shock but not in nonseptic shock patients.

150 equential Organ Failure Assessment scores in septic shock but not in nonseptic shock patients.

151 ided resuscitation strategy in patients with septic shock, but the difference in the primary outcome,

152 sis of sepsis but enables the development of septic shock by maintaining NK cell numbers and integrit

153 R had the best discrimination for predicting septic shock (c-statistic 0.90), respiratory failure req

154 Cardiogenic and septic shock, cardiac arrhythmia, and postsurgical compl

155 Septic shock carries a high mortality risk.

156 s proinflammatory cytokine production during septic shock caused by cecal ligation and puncture or en

157 IL-15 SA treatment also exacerbated septic shock caused by cecal ligation and puncture when

158 The cohorts consisted of 120 patients with septic shock (cohort 1) and 88 patients with S. aureus b

159 inistered to patients with severe sepsis and septic shock compared with usual care.

160 an age greater than 18 years old, fulfilling septic shock criteria according to "Sepsis-3" at accepta

161 ne the outcomes of patients meeting Sepsis-3 septic shock criteria versus patients meeting the "old"

162 ptic shock gene biomarkers may facilitate in septic shock diagnosis, treatment, and prognosis.

163 r hospitalization, 149 (65.0%) had sepsis or septic shock during their course.

164 nting to the emergency department with early septic shock, early goal-directed therapy compared with

165 a 6-hour resuscitation in 688 patients with septic shock enrolled in the ProCESS trial.

166 d 12 months following PICU admission for the septic shock event, 8%, 11%, 12%, and 13% of patients ha

167 randomized controlled trials in the field of septic shock failed to demonstrate a benefit on mortalit

168 improvement initiative for severe sepsis and septic shock focused on the resuscitation bundle on 90-d

169 d febrile neutropenia (five [5%]), sepsis or septic shock (four [4%]), pneumonia (two [2%]), and pyre

170 ve patients presenting with severe sepsis or septic shock from 2011 to 2013.

171 btained serum samples from 529 patients with septic shock from 22 ICUs in Australia and New Zealand.M

172 The identification of the septic shock gene biomarkers may facilitate in septic sh

173 on as a target during resuscitation in early septic shock has not been established.

174 nal capillary density and/or RBC velocity in septic shock, heart failure, hypovolemia, obstructive sh

175 A total of 361,323 severe sepsis or septic shock hospital discharges were included.

176 dney injury was 2.212 (95% CI: 1.334-3.667), septic shock (HR = 1.895, 95% CI: 1.081-3.323) and model

177 rvival benefit was observed in patients with septic shock (HR, 0.80 [CI, .26-2.46]), in NVIE (HR, 0.7

178 s for all patients with suspected sepsis and septic shock, ideally within 1 hour of recognition.

179 revealed the role of caspase-11 in mediating septic shock in response to lethal doses of lipopolysacc

180 a central mediator of systemic inflammation, septic shock in the Plasmodium chabaudi-infected mice an

181 logic studies of pediatric severe sepsis and septic shock in this large, multicenter database.

182 pective observational study of children with septic shock in whom the PERSEVERE biomarkers were measu

183 Septic shock is a devastating health condition caused by

184 Septic shock is a life-threatening condition in which ti

185 Septic shock is a systemic inflammation associated with

186 Cellular Immunotherapy for Septic Shock is the first-in-human clinical trial evalua

187 Septicemia with septic shock is the most common cause of death, with mor

188 repinephrine, the first-line vasopressor for septic shock, is not always effective and has important

189 Further, septic shock, late-onset cardiac dysfunction, and multio

190 osis and prognosis of acute ischemic stroke, septic shock, lung injuries, insulin resistance in diabe

191 Studies have indicated that patients with septic shock may benefit from extracorporeal membrane ox

192 ephrine, the cornerstone vasopressor used in septic shock, may contribute to immune dysregulation and

193 cytokines was assessed in 195 patients with septic shock.Measurements and Main Results: Norepinephri

194 ated AKI on Day 3 (D(3) SA-AKI) in pediatric septic shock.Methods: We performed secondary analysis of

195 ified complications were hepatitis (n = 36), septic shock (n = 22), and pulmonary complications/pneum

196 ded diabetic ketoacidosis (n = 8), sepsis or septic shock (n = 9), and acute kidney injury (n = 4).

197 he chlorambucil plus obinutuzumab group (n=1 septic shock, n=1 metastatic skin squamous carcinoma).

198 he 208 cases of KPC-Kp bacteremia identified septic shock, neutropenia, Charlson comorbidity index >=

199 ntial Organ Failure Assessment scores in the septic shock nonsurvivors patients but not in nonseptic

200 lial and fibrotic proteins was higher in the septic shock nonsurvivors patients but not in nonseptic

201 In this study, we demonstrate that in septic shock O-GlcNAc stimulation improves global animal

202 t failure, sepsis severity (severe sepsis vs septic shock), obesity, Mortality in Emergency Departmen

203 stimate baseline mortality risk in pediatric septic shock.Objectives: To assess the association betwe

204 ting consensus criteria for severe sepsis or septic shock on manual chart review were entered into th

205 atients meeting the "old" (1991) criteria of septic shock only.

206 e ICU admission (OR 5.07, 95% CI 3.18-8.07), septic shock (OR 1.92, 95% CI 0.93-3.98), corticosteroid

207 ST16 (OR 21.4; CI95% 2.3-202.8; p=0,008) and septic shock (OR 11.9; CI95% 4.2-34.1; p<0,001) were ind

208 R 1.943; 95% CI 1.209-3.123), development of septic shock (OR 25.896; 95% CI 8.970-74.765), and the p

209 ence interval [CI], 2.3-202.8; P = .008) and septic shock (OR, 11.9; 95% CI, 4.2-34.1; P < .001) were

210 HLA-A02:01 was associated with lower odds of septic shock [OR 0.52, (0.32-0.82)].

211 base using explicit codes for severe sepsis, septic shock, or Dombrovskiy criteria (concomitant codes

212 r patients admitted to the ICU for sepsis or septic shock over the last 2 decades.

213 Consecutive sample of all severe sepsis and septic shock patients (defined: infection, >/= 2 systemi

214 Circulating endothelial cells from septic shock patients are acutely converted into fibrobl

215 talloid resuscitation provided to sepsis and septic shock patients at initial presentation and 2) det

216 Adult sepsis and septic shock patients captured in a prospective quality

217 Sepsis and septic shock patients had higher maximum ferritin levels

218 he timing of antibiotics and mortality among septic shock patients has not been examined among patien

219 mean arterial pressure with noradrenaline in septic shock patients improves density and flow in small

220 ng samples from 10 healthy volunteers and 20 septic shock patients stratified using human leukocyte a

221 e whether progressive loss of muscle mass in septic shock patients was associated with mortality.

222 es: healthy volunteers, intermediate mHLA-DR septic shock patients, and low mHLA-DR septic shock pati

223 erbate elevated cytokine levels in plasma of septic shock patients, consistent with a safe response.

224 (TNF-alpha) secretion by single monocytes in septic shock patients, to study immune responses by meas

225 allogeneic mesenchymal stem/stromal cells in septic shock patients.

226 mass might be a useful prognostic factor for septic shock patients.

227 a reduction of catecholamine requirements in septic shock patients.

228 LA-DR septic shock patients, and low mHLA-DR septic shock patients.

229 ts (n = 274) diagnosed with severe sepsis or septic shock per Sepsis-2 criteria from September to Nov

230 ated Protein C and Corticosteroids for Human Septic Shock) per patient.

231 e in insured patients with severe sepsis and septic shock post Affordable Care Act.

232 upport outcomes were defined and reported in septic shock randomized controlled trials.

233 Among patients with early septic shock, receipt of HAT was not associated with mor

234 Among patients with septic shock receiving norepinephrine, administration of

235 able intensive care patients with or without septic shock (recommended threshold for RBC transfusion,

236 met consensus criteria for severe sepsis or septic shock (reference standard cohort).

237 hepatitis related to atezolizumab [n=1] and septic shock related to nab-paclitaxel [n=1]) and one (<

238 n septic shock and identified the unexplored septic shock-related genes and functional groups.

239 hypotensive and was admitted to ICU in frank septic shock requiring inotropes, and with demonstrable

240 that included adult patients (n = 868) with septic shock requiring more than 5 mug/min of norepineph

241 Abnormal peripheral perfusion after septic shock resuscitation has been associated with orga

242 ational Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria in the emergency depart

243 ational Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) uses the Sequential Organ Failur

244 ted to the early management of severe sepsis/septic shock (SS/SS) in Emergency Department (ED) has ye

245 l Dictionary for Regulatory Activities toxic/septic shock standardized query.

246 four clusters following early prediction of septic shock, stratifying by outcome: the highest-risk a

247 sus Norepinephrine Infusion in Patients With Septic Shock studies (n=632).

248 and chemokine activity and distinguished the septic shock survivor from non-survivor.

249 nd Simplified Acute Physiology Score II with septic shock survivors (unexposed group).

250 howed discriminatory power between pediatric septic shock survivors and nonsurvivor types.

251 t GNB had a significantly lower incidence of septic shock than nontransplant GNB (10.3% vs 30.7%, p =

252 for >/= 3 days at full dose in patients with septic shock that is not responsive to fluid and moderat

253 irical treatment of patients with sepsis and septic shock, that is, moxifloxacin, meropenem, and pipe

254 In patients with septic shock, the combination of ascorbic acid, corticos

255 0.92-0.98).Conclusions: Among children with septic shock, the PERSEVERE biomarkers predict severe D(

256 acid were not.Conclusions: In patients with septic shock, there was no heterogeneity in effect of ad

257 epsis who are at elevated risk of developing septic shock therefore has the potential to save lives b

258 ation of fluid for infants and children with septic shock (this latter topic was evaluated by evidenc

259 In septic shock, thrombocytopenia is associated with increa

260 of hereditary angioedema and is involved in septic shock, traumatic injury, Alzheimer's disease (AD)

261 all group of patients with severe sepsis and septic shock treated with hydrocortisone, high-dose asco

262 28- and 90-day mortality in Vasopressin and Septic Shock Trial in lactate subgroups.

263 In genotyped patients in the Vasopressin and Septic Shock Trial trial, we found that the 3-Hydroxy-3-

264 sus Norepinephrine Infusion in Patients with Septic Shock Trial) cohort (n = 632) and St.

265 In 632 patients enrolled in Vasopressin and Septic Shock Trial, Proprotein Convertase Subtilisin/Kex

266 ped patients enrolled in the Vasopressin and Septic Shock Trial.

267 patients with AKI in VASST (Vasopressin and Septic Shock Trial; n = 271), and differences in treatme

268 organ support-free days outcome reporting in septic shock trials.

269 ated Protein C and Corticosteroids for Human Septic Shock trials.

270 ated Protein C and Corticosteroids for Human Septic Shock trials.

271 en patients surviving PF and those surviving septic shock unrelated to PF.

272 a double-blind, randomized clinical trial in septic shock (VANISH [Vasopressin vs. Norepinephrine as

273 ntensive care unit (ICU) stay for >24 hours, septic shock, vasoactive agents, positive-pressure venti

274 In cancer patients with septic shock, vasopressin as first-line vasopressor ther

275 tumumab group (the most common being sepsis, septic shock, viral sepsis, and pneumonia).

276 re initiating therapy, whereas patients with septic shock warrant emergent broad-spectrum antibiotics

277 ng intensity during the first 24 hours after septic shock was associated with increased mortality.

278 Transcriptomic profile at onset of septic shock was associated with response to corticoster

279 Septic shock was the main reason for admission mostly of

280 In patients with early septic shock, we compared the association of early HAT t

281 Patients from 5 days to 18 years old with septic shock were enrolled.

282 ncer patients admitted to ICUs for sepsis or septic shock were extracted from the Groupe de Recherche

283 Four-hundred twenty-four patients with septic shock were included between March 2017 and March

284 f 506 patients with S. aureus bacteremia and septic shock were included in the analysis.

285 Thirty-seven survivors of PF and 37 of septic shock were phone-interviewed at 55 (interquartile

286 oclax group (two from pneumonia and one from septic shock) were considered treatment-related; no deat

287 reviewed prospectively enrolled registry of septic shock which had 817 consecutive patients.

288 tcomes of 82 patients (aged >=18 years) with septic shock who received VA-ECMO at five academic ECMO

289 Medical and surgical ICU patients with septic shock who received vasopressin infusion added to

290 tients meeting criteria for severe sepsis or septic shock who were admitted to the ICU from the emerg

291 Two deaths were deemed treatment related (septic shock with 60 mg/m(2); pneumonia with 90 mg/m(2))

292 ong all groups (septic shock: 12.6% to 6.7%; septic shock with acute respiratory failure receiving in

293 patients with septic shock (22.1% to 15.5%), septic shock with acute respiratory failure receiving in

294 ients with septic shock (21.2% to 10.8%) and septic shock with acute respiratory failure receiving in

295 Cure of severe infections, sepsis, and septic shock with antimicrobial drugs is a challenge bec

296 kers can identify subgroups of patients with septic shock with differential treatment responses to hy

297 Hospital survival was 90% for septic shock with left ventricular failure and 64.7% in

298 He was in a septic shock with multiple organ failure up on presentat

299 predict mortality and rate of recovery from septic shock with over 90% accuracy.

300 Patients diagnosed for septic shock within the first 48 hours of ICU admission